It is estimated that more than 2,370 new cases of HPV-associated oropharyngeal cancers are diagnosed in women and nearly 9,356 are diagnosed in men each year in the United States.* These numbers are based on cancers in specific areas of the oropharynx and do not include cancers in all areas of the head and neck or oral cavity. Non-Hispanics and men get these cancers more often than Hispanics and women.
Research and Reports in Tropical Medicine has published the review “Chikungunya virus outbreak expansion and microevolutionary events affecting epidemiology and epidemic potential”.
As corresponding author Dr Ann Powers says “The Chikungunya virus (CHIKV) has been causing ongoing outbreaks throughout the globe for the past decade. In the past year alone, the virus has been transmitted in the western hemisphere affecting a staggering 44 countries with nearly 1.2 million cases.”
A fast-spreading mosquito-borne virus could affect seven in 10 people in Rio de Janeiro, health authorities have warned.
Experts have said it is only a matter of time before chikungunya, which is similar to dengue fever and for which there is no treatment, arrives in the Brazilian city and could fast become an epidemic.
Estimated Primary Completion Date
July 2015 (final data collection date for primary outcome measure)
The human papillomavirus (HPV) is now responsible for more than 60 percent of the cases of oropharyngeal cancer diagnosed at Penn State Milton S. Hershey Medical Center, according to Dr. David Goldenberg, professor of surgery and medicine, and director of Head and Neck Surgery
“It’s just the reality of how these bugs are,” said Patel, the St. Louis University infectious disease expert. “We are in a situation where there will be more bugs. There are going to be more outbreaks. It’s going to be something other than Ebola next time. We have to stay vigilant.”
Inovio has partnered with MedImmune, the global biologics research and development arm of AstraZeneca, to develop and assess DNA-based monoclonal antibodies (mAbs) for influenza and antibiotic resistant bacteria.
3/16/15 $16 million HIV grant received
from NIAID for collaborative study
3/4/15 Nancy Wysenski joins the Board
1/29/15 Dr. Mark Gelder appointed Vice
President, Clinical Development
1/6/15 Immunotherapy shows characteristics
considered vital to treating HIV
12/18/14 Phase I trial for breast, lung
and pancreatic cancers initiated
12/17/14 Zane Yang, M.D. appointed
as Vice President, Clinical Development,
12/15/14 INO added to NASDAQ Biotechnology
11/20/14 Melanoma DNA immunotherapy
inhibits tumor growth and increases
survival in preclinical study
11/17/14 Prostate cancer immunotherapy
will be developed independently by
Inovio. Inovio will maintain its collaboration
with Roche for hep B
16 positions at San Diego and Plymouth Meeting combined.
Senior Manufacturing Engineer II
Associate Director Clinical Compliance
Analytical Assay Scientist
Clinical Program Manager
Senior Electrical Engineer
Senior Mechanical Engineer
Associate Director of Data Management
Clinical Supplies Coordinator
IT Site Support Manager
Electrical Test Technician II
Molecular Biology Research Associate
Production Assembler II
IT Site Support Manager
IT Site Manager
Research Associate I Analytical Sciences
The plan is the result of an order Obama signed in September forming a task force on the issue. Obama also has asked Congress to nearly double its funding to fight antibiotic resistance to $1.2 billion
"Chikungunya continues to be a major threat to public health around the world," said researcher Scott Weaver from the University of Texas Medical Branch at Galveston
Chikungunya, a disease transmitted to humans through mosquito bites, may not be as deadly as dengue but it could hamper a person’s life due to joint pains, an official said yesterday.
Ronald Eullaran of the Philippine Rheumatology Association (PRA) said the joint pains could last for years and could lead to chronic arthritis.
Research and Markets: Global Human Papillomavirus (HPV) Associated Cancer Therapeutics Pipeline Review 2015 - 25 Companies & 33 Drug Profiles
Research and Markets: Global Colitis Therapeutics Pipeline Review 2015 - 11 Companies & 23 Drug Profiles
...and begin treating women in this phase III study in early 2016.
We intend to independently advance VGX-3100 into a phase III registration study with target patient characteristics and a treatment regimen similar to the phase II study.
Meanwhile, PAHO's Feb 27 count of chikungunya cases in the Americas, at 1,250,895, is up by 2,802 since a week earlier. The new total includes 1,222,418 suspected and 24,982 confirmed cases, all locally acquired, plus 3,495 imported cases.
Jurisdictions that reported increased cases included El Salvador, up by 1,383 at 143,172; Honduras, up 1,556 at 6,908; and Puerto Rico, up 1,700 at 30,747.
At the same time, Brazil slashed its case count by 2,627, to 4,116, by eliminating most of the 2,776 confirmed locally acquired cases it had reported previously. The report offered no explanation for the change.
The United States added 18 imported cases to its chikungunya count, for a total of 2,535 cases, with 11 locally acquired ones and the rest imported.
The death toll for the epidemic stayed the same, at 183.
National mosquito experts will gather at The University of Texas at El Paso to discuss and strengthen U.S. border plans related to the surveillance and control of mosquito-borne viruses. The meeting was created to prepare for the likely onslaught of chikungunya, an emerging infectious disease from the Eastern Hemisphere that first appeared in the Caribbean last year; it is expected to spread north to the southern United States
From the summer of 2004 to March of 2005 REGN had similar price action as INO is currently experiencing. From that low point in 2005 it never looked back. It also had a long history of ups and downs prior to that period which destroys the argument that a BIO company with a long existence can't catch fire. It was ugly for the REGN holders then, but any of them with the balls to hold one are feeling good today!